The tumors simply didn't grow when we removed the fructose transporter
In the quiet machinery of the brain's immune landscape, researchers at Northwestern University have found that glioblastoma — one of humanity's most stubborn cancers — does not merely resist the body's defenses, but actively recruits them as accomplices. A study published in PNAS reveals that microglia, the brain's own immune sentinels, are turned against the patient through a fructose metabolism pathway governed by a protein called GLUT5, suppressing the very immune response that might otherwise destroy the tumor. This discovery reframes glioblastoma not as a fortress to be stormed, but as a manipulation of trust — and suggests that interrupting a single metabolic step could restore the immune system's will to fight.
- Glioblastoma remains one of the deadliest and most treatment-resistant brain cancers precisely because it transforms the immune system from adversary into protector.
- Microglia — normally guardians of healthy brain function — are uniquely equipped with the GLUT5 fructose transporter, which the tumor exploits to silence anti-cancer immunity.
- When scientists engineered mice to lack GLUT5, tumors stalled in their growth and the immune system surged back to life, with T-cells and B-cells activating and multiplying with new precision.
- The effect is not confined to microglia alone — blocking fructose metabolism triggers a cascade that reawakens the entire immune ecosystem within the tumor microenvironment.
- Researchers are now moving toward human applications, envisioning GLUT5 blockade not as a cure in itself, but as the key that finally allows immunotherapy to work in patients who have exhausted all other options.
Researchers at Northwestern University have identified an unexpected mechanism by which glioblastoma — an aggressive and largely treatment-resistant brain cancer — disarms the immune system meant to destroy it. The culprit is not the tumor cells alone, but the immune microenvironment they cultivate: a community of cells that has been reprogrammed to shield the cancer rather than attack it.
At the center of this discovery are microglia, immune cells native to the brain that ordinarily support healthy neurological function. In glioblastoma, they are co-opted into a suppressive role. The new study, published in the Proceedings of the National Academy of Sciences, pinpoints how: microglia metabolize fructose through a transporter protein called GLUT5 — and this metabolic process actively dampens the immune response. Crucially, microglia are the only immune cells in the tumor environment capable of this fructose breakdown, making them a precise and promising target.
Led by assistant professor Jason Miska and postdoctoral fellow Leah Billingham, the team genetically removed GLUT5 from mice with glioblastoma. The results were striking: tumors barely grew, and the immune system mounted a far more aggressive response. Without fructose metabolism, microglia shifted from immunosuppressive to inflammatory — and that shift cascaded outward. T-cells and B-cells activated, inflammatory molecules surged, and CD8+ T-cells — the immune system's frontline cancer killers — multiplied and targeted tumor cells with greater accuracy. Billingham was careful to note that the effect was systemic: the microglia's metabolic change set off a chain reaction across the entire immune ecosystem.
The clinical stakes are high. Immunotherapy has transformed outcomes in many cancers but has largely failed in glioblastoma, in part because the tumor microenvironment is so effective at suppressing immune activity. If GLUT5 blockade can flip that suppression into activation, it could serve as a gateway — not a standalone cure, but a means of making immunotherapy viable for patients who have run out of alternatives. The team's next step is translating these findings from mouse models into human trials.
Researchers at Northwestern University have uncovered an unexpected vulnerability in one of the brain's most lethal cancers: the tumor itself is sabotaging the immune system's ability to fight back by hijacking a simple sugar pathway.
The discovery centers on glioblastoma, an aggressive malignant tumor that grows rapidly and resists most treatments. What makes it so formidable is not just the cancer cells themselves, but the ecosystem of immune cells surrounding them—a microenvironment that has evolved to protect the tumor rather than destroy it. Chief among these protective cells are microglia, immune cells that normally support healthy brain function but in this case have been co-opted to work against the patient.
The new study, published in the Proceedings of the National Academy of Sciences, identifies the mechanism: microglia are breaking down fructose—a simple sugar—in a way that actively suppresses the immune response. The process hinges on a protein called GLUT5, a transporter that allows microglia to absorb and metabolize fructose. Microglia are the only immune cells in the glioblastoma microenvironment capable of this particular metabolic trick, making them uniquely vulnerable to intervention.
Jason Miska, an assistant professor of neurological surgery at Northwestern's medical school, led the research. When his team genetically engineered mice to lack the GLUT5 transporter, something striking happened: the tumors simply refused to grow. More than that, the immune system mounted a dramatically stronger response. Without the ability to break down fructose, microglia became more inflammatory rather than immunosuppressive. This shift triggered a cascade: T-cells and B-cells in the tumor became activated, producing more of the inflammatory molecules needed to actually kill cancer cells. CD8+ T-cells—the immune system's primary cancer-fighting force—multiplied rapidly and recognized tumor cells with greater precision.
Leah Billingham, a postdoctoral fellow in Miska's lab and first author of the study, emphasized that this is not a simple one-cell story. "This isn't just solely the microglia doing something," she explained. The fructose metabolism in microglia sets off a chain reaction across the entire immune ecosystem. When microglia stop suppressing immunity, other immune cells wake up. The inflammatory signals they produce are not incidental—they are, the researchers found, actually required for the body to reject the brain tumor.
The implications are substantial. Glioblastoma remains one of the most treatment-resistant brain cancers partly because its microenvironment is so effective at shutting down immune responses. Immunotherapy—training the immune system to recognize and attack cancer—has shown promise in many cancers but often fails in glioblastoma. If blocking fructose metabolism in microglia can flip the tumor's immune suppression into immune activation, it could transform how these patients respond to treatment.
The researchers used multiple analytical techniques, including genetic sequencing, to map exactly which cells were doing what. The evidence was clear: microglia uniquely express GLUT5, and this fructose transporter is essential to their tumor-protective function. Miska noted the surprise in the finding: "We knew microglia use this fructose transporter as part of their normal biology, but we did not expect it to be this important for brain tumour growth." The next step is moving from mouse models toward human trials, where blocking this pathway could become a new therapeutic strategy—not as a standalone treatment, but as a way to make immunotherapy actually work in patients who have run out of options.
Notable Quotes
We knew microglia use this fructose transporter as part of their normal biology, but we did not expect it to be this important for brain tumour growth.— Jason Miska, assistant professor of neurological surgery at Northwestern University
This isn't just solely the microglia doing something; this is an intricate interaction between the different parts of the immune system and how they are then impacting tumour rejection.— Leah Billingham, postdoctoral fellow and first author of the study
The Hearth Conversation Another angle on the story
So the tumor is using the immune system against itself. How does a cancer cell convince an immune cell to help it?
It's not really persuasion—it's more like the tumor creates an environment where certain immune cells find it advantageous to stay quiet. Microglia are supposed to be protective, but in this tumor microenvironment, breaking down fructose actually keeps them in a suppressive state. The tumor doesn't need to trick them; it just needs to feed them the right sugar.
And GLUT5 is the key to that whole process?
Exactly. GLUT5 is the door. Without it, microglia can't absorb fructose, so they can't metabolize it in the way that suppresses immunity. When researchers removed that transporter in mice, the tumors couldn't grow. It's remarkably specific.
Why does fructose metabolism specifically suppress immunity? What's the biochemistry doing?
That's the deeper question the study identifies but doesn't fully answer. The mechanism is there—fructose breakdown in microglia leads to immune suppression—but the exact molecular steps are still being worked out. What matters clinically is that it works, and that it's reversible.
If you block GLUT5, what happens to normal, healthy microglia in the brain?
That's the crucial safety question. Microglia do use GLUT5 in normal brain function, so there's a risk of side effects. But the study suggests the effect is specific enough that it might be manageable. The real test will be in human trials.
How far away is a drug that actually blocks this?
The science is solid, but translating it to patients takes time. You need to develop a compound that reaches the brain, blocks GLUT5 specifically, and doesn't harm healthy tissue. Years, probably. But this gives oncologists a real target to aim at.